Global Oncology Market To 2023 - Robust Growth Driven By Rising Prevalence And Increased Uptake Of Immune Checkpoint Inhibitors

Published Date: Jun-2017 | Pages:420| Category:Pharmaceutical | Report Id-73161

    Single User Price-$ 4,995.00 | Multi User Price-$ 14,985.00

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

Summary

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic. However, they exert more damage on malignant tissue than healthy tissue due to the rapid cell cycle of cancer cells. The key cancer indications of this report are breast, colorectal, lung, and prostate and hematological cancers.

A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Scope

- Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?
- What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications?
- How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?
- What proportion of the key players’ revenues will be attributable to oncology products?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types
- Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers
- Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Symptoms 11
2.3 Diagnosis 12
2.4 Etiology and Pathophysiology 13
2.4.1 Etiology 13
2.4.2 Pathophysiology 15
2.5 Co-morbidities and Complications 16
2.6 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 17
2.6.1 Breast Cancer 17
2.6.2 Colorectal Cancer 18
2.6.3 Lung Cancer 19
2.6.4 Prostate Cancer 20
2.6.5 Hematological Cancers 21
2.7 Prognosis 22
2.7.1 Breast Cancer 22
2.7.2 Colorectal Cancer 23
2.7.3 Non-Small-Cell Lung Cancer 23
2.7.4 Prostate Cancer 24
2.8 Treatment 25
2.8.1 Surgery and Radiation Therapy 25
2.8.2 Chemotherapy 26
2.8.3 Hormonal Therapies 28
2.8.4 Targeted Therapies 29
3 Key Marketed Products 31
3.1 Overview 31
3.2 MabThera/Rituxan (rituximab) 32
3.3 Avastin (bevacizumab) 33
3.4 Herceptin (trastuzumab) 35
3.5 Revlimid (lenalidomide) 37
3.6 Opdivo (nivolumab) 39
3.7 Xtandi (enzalutamide) 41
3.8 Gleevec/Glivec (imatinib mesylate) 42
3.9 Alimta (pemetrexed) 44
3.10 Zytiga (abiraterone acetate) 46
3.11 Conclusion 47
4 Pipeline Landscape Assessment 49
4.1 Overview 49
4.2 Pipeline Development Landscape 50
4.3 Molecular Targets in the Pipeline 54
4.4 Clinical Trials 58
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 58
4.4.2 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target 62
4.4.3 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target 66
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 70
4.4.5 Conclusion 74
4.5 Assessment of Key Pipeline Products 74
4.5.1 Durvalumab - AstraZeneca 74
4.5.2 Durvalumab and Tremelimumab - AstraZeneca 75
4.5.3 Abemaciclib - Eli Lilly 76
4.5.4 Rova-T (rovalpituzumab tesirine) - AbbVie 77
4.5.5 Neratinib - Puma Biotechnology 79
4.5.6 Acalabrutinib - AstraZeneca 80
4.5.7 KTE-C19 (Axicabtagene Ciloleucel) - Kite Pharma 81
4.5.8 Tisagenlecleucel-T - Novartis 83
4.5.9 Conclusion 84
5 Multi-scenario Market Forecast to 2023 85
5.1 Overall Market Size 85
5.2 Generic Penetration 101
5.3 Revenue Forecast by Molecular Target 103
5.3.1 Programmed Cell Death Protein 1/Programmed Cell Death 1 Ligand 1 103
5.3.2 Tumor Necrosis Factor 105
5.3.3 Tyrosine-Protein Kinase BTK 106
5.3.4 Cyclin-Dependent Kinases 107
5.3.5 Androgen Receptor 108
5.3.6 Vascular Endothelial Growth Factor 109
6 Company Analysis and Positioning 110
6.1 Revenue and Market Share Analysis by Company 111
6.1.1 Roche - To What Extent Will Newly Approved and Pipeline Product Approvals Offset the Patent Expiries of Avastin and Herceptin? 116
6.1.2 Celgene - How Will Multiple Patent Expiries Affect Oncology-Related Revenues? 118
6.1.3 Novartis - How Will Mekinist plus Tafinlar and Tasigna Perform over the Forecast Period? 119
6.1.4 Bristol-Myers Squibb - How Successful Will Recent Approvals Opdivo and Empliciti Become? 120
6.1.5 Pfizer - What Do Sutent and Inlyta Patent Expiries Mean for Pfizer? 120
6.1.6 AstraZeneca - How Will its Immune Checkpoint Inhibitors Durvalumab and Tremelimumab Perform? 121
6.2 Company Landscape 123
6.3 Marketed and Pipeline Portfolio Analysis 124
7 Strategic Consolidations 126
7.1 Licensing Deals 126
7.1.1 Deals by Region, Year and Value 126
7.1.2 Deals by Stage of Development and Value 129
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 130
7.1.4 Table for Licensing Deals Valued Above $100m 131
7.2 Co-development Deals 145
7.2.1 Deals by Region, Year and Value 145
7.2.2 Deals by Stage of Development and Value 147
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 148
7.2.4 Table for Co-development Deals Valued $1 billion and Above 149
8 Appendix 156
8.1 References 156
8.2 Abbreviations 417
8.3 Methodology 418
8.3.1 Secondary Research 418
8.3.2 Market Size and Revenue Forecasts 419
8.3.3 Pipeline Analysis 419
8.3.4 Competitive Landscape 419
8.4 Contact Us 420
8.5 Disclaimer 420

Request Sample